Clinical Observation of Shenbitang Combined with Diclofenac Sodium for Osteonecrosis of Femoral Head Caused by Kidney Deficiency and Blood Stasis

QIAO Wei-ping; YUAN Dong

doi:10.13422/j.cnki.syfjx.20181529

您当前的位置：

首页 >

文章列表页 >

Clinical Observation of Shenbitang Combined with Diclofenac Sodium for Osteonecrosis of Femoral Head Caused by Kidney Deficiency and Blood Stasis

更新时间：2024-01-04

- Clinical Observation of Shenbitang Combined with Diclofenac Sodium for Osteonecrosis of Femoral Head Caused by Kidney Deficiency and Blood Stasis
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 17, Pages: 183-188(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20181529
  CLC： R681.8
- Published：2018
- 稿件说明：
移动端阅览
QIAO Wei-ping, YUAN Dong. Clinical Observation of Shenbitang Combined with Diclofenac Sodium for Osteonecrosis of Femoral Head Caused by Kidney Deficiency and Blood Stasis[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(17): 183-188.
DOI：

QIAO Wei-ping, YUAN Dong. Clinical Observation of Shenbitang Combined with Diclofenac Sodium for Osteonecrosis of Femoral Head Caused by Kidney Deficiency and Blood Stasis[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(17): 183-188. DOI： 10.13422/j.cnki.syfjx.20181529.

摘要

目的：探讨肾痹汤加减联合双氯芬酸钠缓释片治疗早中期股骨头坏死肾虚血瘀证的临床疗效，探讨其作用机制。方法：将106例早中期股骨头坏死肾虚血瘀证患者按就诊顺序随机分为对照组和观察组，每组各53例。对照组患者给予仙灵骨葆胶囊联合双氯芬酸钠缓释片，观察组患者给予肾痹汤加减联合双氯芬酸钠缓释片，连续治疗6个月，随访12个月。治疗前后分别观察患者的Harris量表，健康调查简表（SF-36），中医证候量表和影像学评分；检测血浆黏度（PV），红细胞电泳时间（EPT），红细胞沉降率（ESR），红细胞比容（HCT）的变化；比较两组患者的有效率、复发率及安全性指标。结果：研究期间对照组患者脱落2例，观察组患者脱落4例。观察组总有效率97.9%，高于对照组的82.4%（P<0.05）；随访12个月观察组复发率8.1%，低于对照组的35.5%（P<0.05）。与对照组治疗后比较，观察组患者Harri量表，SF-36量表和髋关节影像学评分明显升高（P<0.05），中医证候量表评分，PV，EPT，ESR，HCT水平明显降低（P<0.05）。观察组不良反应发生率12.2%，低于对照组的35.5%（P<0.05）。治疗组血、尿常规异常发生率分别为15.9%，9.8%，低于对照组的30.6%，18.4%（P<0.05）。结论：肾痹汤加减联合双氯芬酸钠缓释片治疗早中期股骨头坏死肾虚血瘀证，患者的临床症状和PV，EPT，ESR，HCT水平明显改善，复发率和不良反应发生率低。

Abstract

Objective:To explore the therapeutic effect of Shenbitang combined with diclofenac sodium for early-to-middle stage osteonecrosis of the femoral head caused by kidney deficiency and blood stasis. Method:A total of 106 cases eligible patients were randomly divided into the control group (53 cases) and the observation group (53 cases). The patients in control group were treated with Xianling Gubao capsules combined with diclofenac sodium release tablets; Shenbitang combined with diclofenac sodium release tablets was adopted in the observation group

with a treatment course of 6 months and a follow-up of 12 months in both groups.The Harris scale

SF-36

the traditional Chinese medicine(TCM) syndromes scale and imaging scores were observed before and after treatment. The changes of plasma viscosity (PV)

electrophoresis (EPT)

erythrocyte sedimentation rate (ESR)

erythrocyte deposition (HCT) were detected. The effective rates

recurrence rates and safety indexes were compared between two groups. Result:The 2 cases in control group and 4 cases in observation group withdrew from the study. The total effective rate was 97.9% in observation group

higher than 82.4% in control group (P<0.05). The recurrence rate was 8.1% in observation group

lower than 35.5% in control group in follow-up for 12 months (P<0.05). As compared with the control group after treatment

the Harris scores

the SF-36 scores

and hip imaging scores were significantly higher in observation group (P<0.05)

and the TCM syndrome scores

EPT

ESR

and HCT indexes were significantly lower (P<0.05). The incidence of adverse reactions was 12.2% in observation group

lower than 35.5% in control group (P<0.05). The incidence rate of abnormal indexes in routine blood test and urine test was 15.9% and 9.8% respectively in observation group

lower than 30.6% and 18.4% in control group (P<0.05). Conclusion:Shenbitang combined with diclofenac sodium release tablets could significantly improve the clinical symptoms and PV

EPT

ESR and HCT indexes

and reduce the recurrence rate and incidence of adverse reactions in the treatment of early-to-middle stage osteonecrosis of the femoral head caused by kidney deficiency and blood stasis.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Traditional Chinese Medicine in Prevention and Treatment of Osteonecrosis of Femoral Head Based on OPG/RANK/RANKL Signaling Pathway： A Review

Modified Wenjingtang Affects Caspase-8， MMP-9， N-cadherin and E-cadherin in Local Microenvironment of EM Rats with Kidney Deficiency and Blood Stasis

Research Advances of Traditional Chinese Medicine in Treating Osteonecrosis of Femoral Head by Regulating Bone MetabolismRelated Signaling Pathways

Clinical Analysis of "Different Diseases Saring Same Syndrome" Concept in End Stage of Different Hip Diseases

Effect of Modified Shoutaiwan on Recurrent Abortion Due to Prethrombotic Status and Effect on Coagulation Factors

Related Author

LIU Jianjun

LIU Xiaoting

AN Wenbo

GONG Yusuo

YUAN Baohua

HUANG Kang

LIU Tongke

KANG Fuping

Related Institution

Gansu University of Chinese Medicine

Affiliated Hospital of Gansu University of Chinese Medicine

Gansu Provincial Hospital of Traditional Chinese Medicine

Shanxi University of Chinese Medicine

Graduate School，Anhui University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰